Lynk Pharma, Simcere licensing deal for development of novel JAK1 inhibitor LNK01001 in China
Lynk Pharmaceuticals Co., Ltd. and Simcere announced a strategic partnership to develop and commercialize a highly selective JAK1 inhibitor LNK01001 in China.... Read More
Insight on AstraZeneca’s global R&D Postdoctoral Challenge initiative
AstraZeneca launched a global R&D Postdoctoral Challenge to help accelerate ideas to transform the treatment of some of the world’s most complex... Read More
Aqilion buys rights to Phase-I ready anti-inflammatory program from LEO Pharma
Swedish life science company Aqilion has acquired all rights to Regulus, a Phase I-ready anti-inflammatory program, from Denmark-headquartered dermatology specialist LEO Pharma,... Read More
SPARC entered into a licensing agreement with Biomodifying
Sun Pharma Advanced Research Company (SPARC) has entered into a licensing agreement with Biomodifying to acquire exclusive rights for antibody against unique... Read More
Pharma Case Study: Merck’s $11.5B acquisition of Acceleron
Posted on03 Oct 2021
Comments0
Merck will acquire Acceleron Pharma, Inc. XLRN for $180 per share in cash for an approximate total equity value of $11.5 billion... Read More
Takeda and Frazier announced a collaboration to launch HilleVax, Inc, a biopharmaceutical company, to develop and commercialize Takeda’s norovirus vaccine candidate
Takeda Pharmaceutical Company Limited and Frazier Healthcare Partners announced a collaboration to launch HilleVax, Inc, a biopharmaceutical company, to develop and commercialize... Read More
Case Insight: Piramal Pharma’s acquisition of Hemmo Pharmaceuticals
Piramal Pharma Ltd has completed the acquisition of Hemmo Pharmaceuticals. In March this year, Piramal Pharma Ltd entered into an agreement to... Read More
FDA Grants Accelerated Approval for Alzheimer’s drug Aduhelm
Posted on10 Jun 2021
Tagsaducanumab, Aduhelm, Biogen, Eisai, global pharma licensing deal, monoclonal antibody, Neurimmune, pharma deal
Comments0
USFDA approved Aduhelm (aducanumab) for the treatment of Alzheimer disease. Alzheimer’s drug Aduhelm is research molecule of Neurimmune. Neurimmune licensed its antibody... Read More
Corbus Pharma in-licenses two integrin targeting MAbs
US biotech Corbus Pharmaceuticals (Nasdaq: CRBP) today announced the expansion of its portfolio into immuno-oncology through licensing deals for two new monoclonal... Read More
Insight on Sun Pharma’s Licensing Agreement with Ferring Pharmaceutical for Caritec in India
Sun Pharmaceutical Industries entered into a licensing agreement with Ferring Pharmaceuticals to commercialise innovative obstetric drug Caritec in India. One of the... Read More